Literature DB >> 1989659

Ototoxicity of cisplatinum.

P Brock, S Bellman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1989659      PMCID： PMC1971632          DOI： 10.1038/bjc.1991.35

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  1 in total

1.  Ototoxicity of cisplatinum in children and adolescents.

Authors:  R Skinner; A D Pearson; H A Amineddine; D B Mathias; A W Craft
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640
  1 in total
  7 in total

1.  Evaluation of audiometric threshold shift criteria for ototoxicity monitoring.

Authors:  Dawn Konrad-Martin; Kenneth E James; Jane S Gordon; Kelly M Reavis; David S Phillips; Gene W Bratt; Stephen A Fausti
Journal:  J Am Acad Audiol       Date:  2010-05       Impact factor: 1.664

2.  Prognostic Factors for the Therapeutic Performance of Cisplatin in Head and Neck Malignancies.

Authors:  Frederic Jungbauer; Lena Huber; Sonja Ludwig; Nicole Rotter; Beatrice Walter; Lena Zaubitzer; Anne Lammert
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

Review 3.  Cancer pharmacogenomics in children: research initiatives and progress to date.

Authors:  Shahrad Rod Rassekh; Colin J D Ross; Bruce C Carleton; Michael R Hayden
Journal:  Paediatr Drugs       Date:  2013-04       Impact factor: 3.022

4.  Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Authors:  Colin J D Ross; Hagit Katzov-Eckert; Marie-Pierre Dubé; Beth Brooks; S Rod Rassekh; Amina Barhdadi; Yassamin Feroz-Zada; Henk Visscher; Andrew M K Brown; Michael J Rieder; Paul C Rogers; Michael S Phillips; Bruce C Carleton; Michael R Hayden
Journal:  Nat Genet       Date:  2009-11-08       Impact factor: 38.330

5.  Hearing evaluation of patients with head and neck cancer: Comparison of Common Terminology Criteria for Adverse Events, Brock and Chang adverse event criteria in patients receiving cisplatin.

Authors:  A Dimitrios Colevas; Ruth R Lira; Electra A Colevas; Philip W Lavori; Cato Chan; David B Shultz; Kay W Chang
Journal:  Head Neck       Date:  2014-07-11       Impact factor: 3.147

Review 6.  Using germline genomics to individualize pediatric cancer treatments.

Authors:  Navin Pinto; Susan L Cohn; M Eileen Dolan
Journal:  Clin Cancer Res       Date:  2012-05-15       Impact factor: 12.531

7.  Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.

Authors:  C Bokemeyer; C C Berger; J T Hartmann; C Kollmannsberger; H J Schmoll; M A Kuczyk; L Kanz
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.